Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT05384119
Title	Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer
Recruitment	Completed
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Tvardi Therapeutics, Incorporated
Indications	Her2-receptor negative breast cancer
Therapies	C188-9 + Palbociclib C188-9 + Fulvestrant C188-9 + Ribociclib Fulvestrant
Age Groups:	senior \| adult
Covered Countries	USA